Similar Trends in Serum VEGF-D Levels and Kidney Angiomyolipoma Responses with Longer Duration Sirolimus Treatment in Adults with Tuberous Sclerosis

Izabela A. Malinowska, Nancy Lee, Vidhya Kumar, Elizabeth A. Thiele, David Neal Franz, Stephen Ashwal, Arthur Sagalowsky, Francis J. DiMario, Drew Cutler, Darcy Krueger, Susana Camposano, Jan Paolini, Sandra L. Dabora

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Context: We have previously shown that serum VEGF-D is elevated at baseline, correlates with kidney angiomyolipoma size at baseline and 12 months, and decreases with sirolimus treatment in adults with tuberous sclerosis complex (TSC). To further investigate the utility of serum VEGF-D for longer term monitoring of TSC kidney disease, we present VEGF-D level results with 24 month follow-up. Objective: To compare 24 month VEGF-D levels in two subgroups of sirolimus treated patients (OFF SIROLIMUS AFTER 12 MONTHS or ON SIROLIMUS AFTER 12 MONTHS). Design and Intervention(s): Serum VEGF-D was measured in samples collected from subjects enrolled in a phase 2 multicenter trial evaluating sirolimus for the treatment of kidney angiomyolipomas associated with TSC or TSC/LAM. All participants were treated with sirolimus from 0-12 months. During months 12-24, sirolimus was discontinued in one subgroup. The other subgroup was treated with additional sirolimus. Setting: Adult TSC participants were recruited from six clinical sites in the United States (comprehensive TSC clinics, 5; urology clinic, 1). Patients: There were 28 TSC patients who completed all 24 months of the study and serum samples were available at 24 months from 18/28 patients. Main Outcome Measure(s): We compared the percent change in VEGF-D levels (baseline to 24 months) in patients from the two treatment subgroups. Results: At 24 months, VEGF-D levels decreased by 67% compared with baseline (to 787±426 pg/ml) in the ON SIROLIMUS AFTER 12 MONTHS group versus a 13% decrease (to 2971±4014 pg/ml) in the OFF SIROLIMUS AFTER 12 MONTHS group (p = 0.013, Mann-Whitney test). A similar trend was observed in kidney angiomyolipoma size but not in pulmonary function tests. Conclusions Serum VEGF-D may be useful for monitoring response to treatment with sirolimus and kidney angiomyolipoma size in patients with TSC, but confirmation is needed. Trial Registration: Clinical trials.gov NCT00126672.

Original languageEnglish (US)
Article numbere56199
JournalPLoS One
Volume8
Issue number2
DOIs
StatePublished - Feb 20 2013

Fingerprint

vascular endothelial growth factor D
Vascular Endothelial Growth Factor D
Angiomyolipoma
Tuberous Sclerosis
sclerosis
Sirolimus
kidneys
Kidney
duration
Serum
Therapeutics
Urology
monitoring
lung function
Monitoring
kidney diseases
Respiratory Function Tests
Kidney Diseases
clinical trials
Multicenter Studies

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Similar Trends in Serum VEGF-D Levels and Kidney Angiomyolipoma Responses with Longer Duration Sirolimus Treatment in Adults with Tuberous Sclerosis. / Malinowska, Izabela A.; Lee, Nancy; Kumar, Vidhya; Thiele, Elizabeth A.; Franz, David Neal; Ashwal, Stephen; Sagalowsky, Arthur; DiMario, Francis J.; Cutler, Drew; Krueger, Darcy; Camposano, Susana; Paolini, Jan; Dabora, Sandra L.

In: PLoS One, Vol. 8, No. 2, e56199, 20.02.2013.

Research output: Contribution to journalArticle

Malinowska, IA, Lee, N, Kumar, V, Thiele, EA, Franz, DN, Ashwal, S, Sagalowsky, A, DiMario, FJ, Cutler, D, Krueger, D, Camposano, S, Paolini, J & Dabora, SL 2013, 'Similar Trends in Serum VEGF-D Levels and Kidney Angiomyolipoma Responses with Longer Duration Sirolimus Treatment in Adults with Tuberous Sclerosis', PLoS One, vol. 8, no. 2, e56199. https://doi.org/10.1371/journal.pone.0056199
Malinowska, Izabela A. ; Lee, Nancy ; Kumar, Vidhya ; Thiele, Elizabeth A. ; Franz, David Neal ; Ashwal, Stephen ; Sagalowsky, Arthur ; DiMario, Francis J. ; Cutler, Drew ; Krueger, Darcy ; Camposano, Susana ; Paolini, Jan ; Dabora, Sandra L. / Similar Trends in Serum VEGF-D Levels and Kidney Angiomyolipoma Responses with Longer Duration Sirolimus Treatment in Adults with Tuberous Sclerosis. In: PLoS One. 2013 ; Vol. 8, No. 2.
@article{bacfe47761c241178892e57be8f48f45,
title = "Similar Trends in Serum VEGF-D Levels and Kidney Angiomyolipoma Responses with Longer Duration Sirolimus Treatment in Adults with Tuberous Sclerosis",
abstract = "Context: We have previously shown that serum VEGF-D is elevated at baseline, correlates with kidney angiomyolipoma size at baseline and 12 months, and decreases with sirolimus treatment in adults with tuberous sclerosis complex (TSC). To further investigate the utility of serum VEGF-D for longer term monitoring of TSC kidney disease, we present VEGF-D level results with 24 month follow-up. Objective: To compare 24 month VEGF-D levels in two subgroups of sirolimus treated patients (OFF SIROLIMUS AFTER 12 MONTHS or ON SIROLIMUS AFTER 12 MONTHS). Design and Intervention(s): Serum VEGF-D was measured in samples collected from subjects enrolled in a phase 2 multicenter trial evaluating sirolimus for the treatment of kidney angiomyolipomas associated with TSC or TSC/LAM. All participants were treated with sirolimus from 0-12 months. During months 12-24, sirolimus was discontinued in one subgroup. The other subgroup was treated with additional sirolimus. Setting: Adult TSC participants were recruited from six clinical sites in the United States (comprehensive TSC clinics, 5; urology clinic, 1). Patients: There were 28 TSC patients who completed all 24 months of the study and serum samples were available at 24 months from 18/28 patients. Main Outcome Measure(s): We compared the percent change in VEGF-D levels (baseline to 24 months) in patients from the two treatment subgroups. Results: At 24 months, VEGF-D levels decreased by 67{\%} compared with baseline (to 787±426 pg/ml) in the ON SIROLIMUS AFTER 12 MONTHS group versus a 13{\%} decrease (to 2971±4014 pg/ml) in the OFF SIROLIMUS AFTER 12 MONTHS group (p = 0.013, Mann-Whitney test). A similar trend was observed in kidney angiomyolipoma size but not in pulmonary function tests. Conclusions Serum VEGF-D may be useful for monitoring response to treatment with sirolimus and kidney angiomyolipoma size in patients with TSC, but confirmation is needed. Trial Registration: Clinical trials.gov NCT00126672.",
author = "Malinowska, {Izabela A.} and Nancy Lee and Vidhya Kumar and Thiele, {Elizabeth A.} and Franz, {David Neal} and Stephen Ashwal and Arthur Sagalowsky and DiMario, {Francis J.} and Drew Cutler and Darcy Krueger and Susana Camposano and Jan Paolini and Dabora, {Sandra L.}",
year = "2013",
month = "2",
day = "20",
doi = "10.1371/journal.pone.0056199",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Similar Trends in Serum VEGF-D Levels and Kidney Angiomyolipoma Responses with Longer Duration Sirolimus Treatment in Adults with Tuberous Sclerosis

AU - Malinowska, Izabela A.

AU - Lee, Nancy

AU - Kumar, Vidhya

AU - Thiele, Elizabeth A.

AU - Franz, David Neal

AU - Ashwal, Stephen

AU - Sagalowsky, Arthur

AU - DiMario, Francis J.

AU - Cutler, Drew

AU - Krueger, Darcy

AU - Camposano, Susana

AU - Paolini, Jan

AU - Dabora, Sandra L.

PY - 2013/2/20

Y1 - 2013/2/20

N2 - Context: We have previously shown that serum VEGF-D is elevated at baseline, correlates with kidney angiomyolipoma size at baseline and 12 months, and decreases with sirolimus treatment in adults with tuberous sclerosis complex (TSC). To further investigate the utility of serum VEGF-D for longer term monitoring of TSC kidney disease, we present VEGF-D level results with 24 month follow-up. Objective: To compare 24 month VEGF-D levels in two subgroups of sirolimus treated patients (OFF SIROLIMUS AFTER 12 MONTHS or ON SIROLIMUS AFTER 12 MONTHS). Design and Intervention(s): Serum VEGF-D was measured in samples collected from subjects enrolled in a phase 2 multicenter trial evaluating sirolimus for the treatment of kidney angiomyolipomas associated with TSC or TSC/LAM. All participants were treated with sirolimus from 0-12 months. During months 12-24, sirolimus was discontinued in one subgroup. The other subgroup was treated with additional sirolimus. Setting: Adult TSC participants were recruited from six clinical sites in the United States (comprehensive TSC clinics, 5; urology clinic, 1). Patients: There were 28 TSC patients who completed all 24 months of the study and serum samples were available at 24 months from 18/28 patients. Main Outcome Measure(s): We compared the percent change in VEGF-D levels (baseline to 24 months) in patients from the two treatment subgroups. Results: At 24 months, VEGF-D levels decreased by 67% compared with baseline (to 787±426 pg/ml) in the ON SIROLIMUS AFTER 12 MONTHS group versus a 13% decrease (to 2971±4014 pg/ml) in the OFF SIROLIMUS AFTER 12 MONTHS group (p = 0.013, Mann-Whitney test). A similar trend was observed in kidney angiomyolipoma size but not in pulmonary function tests. Conclusions Serum VEGF-D may be useful for monitoring response to treatment with sirolimus and kidney angiomyolipoma size in patients with TSC, but confirmation is needed. Trial Registration: Clinical trials.gov NCT00126672.

AB - Context: We have previously shown that serum VEGF-D is elevated at baseline, correlates with kidney angiomyolipoma size at baseline and 12 months, and decreases with sirolimus treatment in adults with tuberous sclerosis complex (TSC). To further investigate the utility of serum VEGF-D for longer term monitoring of TSC kidney disease, we present VEGF-D level results with 24 month follow-up. Objective: To compare 24 month VEGF-D levels in two subgroups of sirolimus treated patients (OFF SIROLIMUS AFTER 12 MONTHS or ON SIROLIMUS AFTER 12 MONTHS). Design and Intervention(s): Serum VEGF-D was measured in samples collected from subjects enrolled in a phase 2 multicenter trial evaluating sirolimus for the treatment of kidney angiomyolipomas associated with TSC or TSC/LAM. All participants were treated with sirolimus from 0-12 months. During months 12-24, sirolimus was discontinued in one subgroup. The other subgroup was treated with additional sirolimus. Setting: Adult TSC participants were recruited from six clinical sites in the United States (comprehensive TSC clinics, 5; urology clinic, 1). Patients: There were 28 TSC patients who completed all 24 months of the study and serum samples were available at 24 months from 18/28 patients. Main Outcome Measure(s): We compared the percent change in VEGF-D levels (baseline to 24 months) in patients from the two treatment subgroups. Results: At 24 months, VEGF-D levels decreased by 67% compared with baseline (to 787±426 pg/ml) in the ON SIROLIMUS AFTER 12 MONTHS group versus a 13% decrease (to 2971±4014 pg/ml) in the OFF SIROLIMUS AFTER 12 MONTHS group (p = 0.013, Mann-Whitney test). A similar trend was observed in kidney angiomyolipoma size but not in pulmonary function tests. Conclusions Serum VEGF-D may be useful for monitoring response to treatment with sirolimus and kidney angiomyolipoma size in patients with TSC, but confirmation is needed. Trial Registration: Clinical trials.gov NCT00126672.

UR - http://www.scopus.com/inward/record.url?scp=84874243150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874243150&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0056199

DO - 10.1371/journal.pone.0056199

M3 - Article

C2 - 23437092

AN - SCOPUS:84874243150

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e56199

ER -